QTTB Key Statistics, Chart & Performance
The current stock price of QTTB is 3.2 USD. In the past month the price decreased by -16.23%. In the past year, price decreased by -18.16%.
QTTB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.31 | 406.04B | ||
| AMGN | AMGEN INC | 15.03 | 176.99B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.14 | 115.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.92 | 52.48B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 31.74B | ||
| BIIB | BIOGEN INC | 10.54 | 25.88B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.8 | 21.37B | ||
| INCY | INCYTE CORP | 15.41 | 19.42B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About QTTB
Company Profile
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2018-03-28. The firm is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The firm is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb - CR1 fusion protein which demonstrated preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.
Company Info
Q32 BIO INC
830 Winter Street
Waltham MASSACHUSETTS US
Employees: 26
Phone: 17819990232
Q32 BIO INC / QTTB FAQ
Can you describe the business of Q32 BIO INC?
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2018-03-28. The firm is focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases. The firm is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Additional discovery and earlier development efforts from its complement inhibitor platform include ADX-096, a C3d mAb - CR1 fusion protein which demonstrated preclinical data supportive of its use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.
What is the stock price of Q32 BIO INC today?
The current stock price of QTTB is 3.2 USD.
Does Q32 BIO INC pay dividends?
QTTB does not pay a dividend.
How is the ChartMill rating for Q32 BIO INC?
QTTB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for QTTB stock?
Q32 BIO INC (QTTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.44).
What is the market capitalization of QTTB stock?
Q32 BIO INC (QTTB) has a market capitalization of 39.36M USD. This makes QTTB a Nano Cap stock.
When does Q32 BIO INC (QTTB) report earnings?
Q32 BIO INC (QTTB) will report earnings on 2026-05-06.
QTTB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to QTTB. When comparing the yearly performance of all stocks, QTTB is one of the better performing stocks in the market, outperforming 84.18% of all stocks.
QTTB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QTTB. QTTB may be in some trouble as it scores bad on both profitability and health.
QTTB Financial Highlights
Over the last trailing twelve months QTTB reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS increased by 84.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.58% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
QTTB Forecast & Estimates
8 analysts have analysed QTTB and the average price target is 11.56 USD. This implies a price increase of 261.25% is expected in the next year compared to the current price of 3.2.